Appointments

The University of Ottawa Heart Institute (UOHI) announces the appointment of Dr. Marc Ruel as cardiac surgeon and Endowed Chair of Cardiac Surgery Research, UOHI and chief of Cardiac Surgery. His fi ve-year mandate will start on Jan. 1, 2013. Dr. Ruel received his M.D. cum laude from the University of Ottawa in 1994 and his specialist certifi cation in Cardiac

Surgery in 2000. He then pursued a combined fellowship in minimally invasive surgery and laboratory research at Harvard University, where he also completed a Masters in Public Health, with a focus on statistical methods. Dr. Ruel’s faculty appointments at the University of Ottawa are with the departments of surgery, cellular and molecular medicine, and epidemiology and community medicine. He is the Chair of the Heart Transplantation and Ventricular Assist Devices Committee, and of the Operating Room Committee at UOHI.

Diane Gosselin has been appointed as the new president and CEO of the Québec Consortium for Drug Discovery (CQDM). Gosselin will be replacing Max Fehlmann, who resigned from CQDM to become the CEO of the new Neomed Institute. Fehlmann will stay on at the CQDM as strategic advisor and a member of the board of directors. Gosselin joined the CQDM in September 2008, as vice president, Research and Business Development, and was responsible for establishing all funding programs and managing the CQDM’s corporate development activities. She has over 20 years of experience in research and corporate fi nancing, namely at Fonds de solidarité FTQ where she helped several companies implement their drug development strategy. At PROCREA BioSciences, she supervised the research team that created and developed the fi rst non-invasive diagnostic test for endometriosis. Gosselin has a Ph.D. in microbiology and immunology from Université de Montréal, as well as an Executive MBA from the Université du Québec à Montréal and Université Paris-Dauphine.

Valeant Pharmaceuticals International, Inc. has named Ryan Weldon and Jason Hanson to its executive management team. Weldon will assume the role of executive vice president/company group chairman where he will lead the U.S. Dermatology Operations, including prescription dermatology, aesthetics and podiatry. Weldon will be relocating to Arizona where these operations will be headquartered. Hanson will relocate to New Jersey where he will assume the role of executive vice president/ company group chairman and lead certain U.S and international businesses and functions to be named later. In addition, Vince Ippolito has been appointed senior vice president, general manager, Aesthetics and Justin Smith will be appointed senior vice president, general manager U.S. Rx Dermatology.

Microbix Biosystems Inc. has appointed Vaughn Embro-Pantalony as president and CEO succeeding William J. Gastle who becomes executive chairman. EmbroPantalony has been a member of the Microbix board of directors and audit committee since 2007. He has held senior executive roles in large biopharmaceutical and agriculture companies, including CFO at Novopharm Ltd and Bayer Healthcare, CIO at Bayer Inc and general manager of Terra Canada’s Nitrogen Division. Most recently he was CEO of StratPath Management Inc., consulting with life science companies on strategy and governance issues. EmbroPantalony has a BA in Economics, an MBA, is a Fellow of the Society of Management Accountants of Canada and holds the designations Chartered Director and Audit Committee Certifi ed. The company also announces that Phil Casselli, previously president of Microbix, is appointed to senior vice-president, sales and business development.

Ostara Nutrient Recovery Technologies Inc. announces the appointment of Scott McDonald as executive vice president and chief fi nancial offi cer. McDonald began his career in fi nance, and quickly rose to the role of chief fi nancial offi cer at several high-tech companies where he led two initial public offerings and multiple merger and acquisition transactions. He also was CEO at Castelle - a public company - from 2002 to 2008. He has served on various corporate boards, in both the public and private sector. He holds a BS Accounting from The University of Akron, and an MBA in Management from Golden Gate University.

Oncolytics Biotech Inc. has appointed Kirk Look to the role of CFO. Look has served as Oncolytics’ controller since 2003 and has been the chief fi nancial offi cer of Oncolytics Biotech (U.S.) Inc. since 2009. Prior to joining Oncolytics, he held senior audit roles with Ernst & Young LLP in both North and South America over an eight year period. He holds a Bachelor of Commerce degree from the University of Calgary and is a Chartered Accountant.

Medical technologies company Covalon Technologies Ltd. announces the appointment of Abe Schwartz as chairman of the board of directors. Schwartz is the founder and president of Schwartz Technologies Corporation, which is actively involved in the fi nancing, development and managing of healthcare and information technology companies. He has served as an advisor to the Covalon board of directors and a company shareholder. He has held executive positions in various public and private companies. Martin Bernholtz has stepped down as chairman of the board and will continue as a board director and chairman of Covalon’s Audit Committee. Bernholtz has been a director since May 2006 and Chairman of the Board since January 2010. The company also announced the appointment of Rita Jairam as CFO. Jairam has held a senior fi nancial position with Covalon since the company’s inception and has been the company’s corporate controller since 2005. She has over 20 years of professional fi nance and accounting experience with various healthcare and real estate companies and is a Canadian certifi ed general accountant.

Stellar Pharmaceuticals Inc. and its operating division, Tribute Pharmaceuticals announces the appointment of Dr. Bernard Chiasson to the newly created position of CSO. Dr. Chiasson is a trained neuroscientist and pharmacologist and will lead the scientifi c and regulatory affairs worldwide for Stellar’s proprietary products as well as its growing portfolio of in-licensed products. Dr. Chiasson recently served as vice president, U.S. Strategic Regulatory and Global Medical Services at OptumInsight (Life Sciences Group), a division of UnitedHealth Group. Prior to his position at OptumInsight, he was director, Regional Medical Liaisons and Medical Services, North American Scientifi c Affairs for Amgen Canada. He was also employed by Bayer Healthcare Canada as director, Scientifi c Development Biologic, Products for Canada, as part of the Canada, Japan and developing markets group.

MethylGene Inc. has appointed Dr. Charles M. Baum to the position of president and CEO. In his new role he has also joined the company’s board of directors. Dr. Baum was most recently senior vice president for clinical research within Pfi zer’s Worldwide Research & Development division. He has worked at Pfi zer since 2003, including as vice president and head of the oncology development and CMO for Pfi zer’s Biotherapeutics and Bioinnovation Center, a Pfi zer division comprised of small biotech research units. Prior to joining Pfi zer Dr. Baum was responsible for the development of several oncology compounds at Schering-Plough, including temozolomide (Temodar®). His career also includes academic and hospital positions at Stanford and Emory Universities, as well as positions of increasing responsibility within the pharmaceutical industry (Systemix, Searle, Schering-Plough and Pfi zer).